Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional CD8+ T cells in patients with pancreatic ductal adenocarcinoma (PDAC), potentially delaying disease recurrence.

In a small trial, nearly half of pancreatic cancer patients who received an mRNA vaccine for the disease had no relapse three years later.

Results from a trial of an mRNA vaccine for pancreatic cancer have shown that the vaccine reduces the chance of the cancer recurring in patients who initially respond.